

Organized by

Supported By

An Initiative By



REVIEW

## BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

VIRTUAL SUMMIT

8 January 2021

15.30 - 17.25 Hrs Singapore Time

15:30 - 15:40

Topics Presented By:

**LIM GEOK HOON, SINGAPORE**

- Radioactive Iodine Seed placement in the Axilla with Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer: results of the prospective multicenter RISAS trial

15:40 - 15:45

Q & A

15:45 - 15:55

Topics Presented By:

**FAYE LIM, SINGAPORE**

- Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women  $\geq$  65 years with early invasive breast cancer: 10 year results
- A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)

15:55 - 16:00

Q & A

16:00 - 16:20

Topics Presented By:

**SHAHEENAH DAWOOD, UAE**

- Final invasive disease-free survival analysis of monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
- Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancer and with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B
- 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ

16:20 - 16:25

Q & A

16:25 - 16:35

Topics Presented By:

**TIRA TAN, SINGAPORE**

- Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant part of ADAPT HR+/HER2- trial
- Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study

apbcs.org

Organized by

Supported By

An Initiative By



## BEST OF SAN ANTONIO BREAST CANCER SYMPOSIUM

### VIRTUAL SUMMIT

8 January 2021

15.30 - 17.25 Hrs Singapore Time

16.35 - 16.40

Q & A

16.40 - 17.05

Topics Presented By:

**WONG NAN SOON, SINGAPORE**

- Adjuvant trial randomized ER+ patients who had a Recurrence Score < 25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy.
- Development and validation of a tool integrating the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
- How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
- Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: First efficacy results from the ADAPT HR+/HER2- trial (n=4,690)

17.05 - 17.10

Q & A

17.10 - 17.35

Topics Presented By:

**JOLINE LIM, SINGAPORE**

- Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
- Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
- Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
- Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies

17.35 - 17.40

Q & A

[apbcs.org](http://apbcs.org)